Combination treatment for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for people with a specific type of advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is a type called RAS wild-type colorectal cancer that has spread to other parts of the body.
- You have already tried chemotherapy that includes oxaliplatin or irinotecan.
- You have already tried treatments that target blood vessel growth or the EGFR protein (for left-sided tumors).
- If your tumor has high microsatellite instability or mismatch repair deficiency, you must have also tried immunotherapy (PD-1/PD-L1 inhibitor).
- Your tumor does not have a BRAF mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
This trial tests a combination of targeted drugs for people with advanced colorectal cancer that has not responded to prior treatment. The drugs aim to block cancer growth by targeting specific gene changes and may boost the immune system to fight the cancer.
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
This study tests a new combination of drugs (Envafolimab, Cetuxima-β, and mFOLFOX6) for people with a specific type of advanced colorectal cancer that has not been treated yet. It aims to see if this combination is safe and more effective than standard treatments.
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
This trial is testing a new combination of three drugs (cetuximab, envolimab, and a chemo called mFOLFOX6) for people with advanced colorectal cancer that has not been treated yet. The goal is to see if this combination is safe and works better than standard treatments.
Hear when a new RAS Wild Type mCRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.